阿法替尼
埃罗替尼
西妥昔单抗
吉非替尼
医学
肺癌
表皮生长因子受体
单克隆抗体
酪氨酸激酶
肿瘤科
临床试验
癌症研究
内科学
癌症
免疫学
抗体
受体
作者
Masayuki Takeda,Kazuhiko Nakagawa
出处
期刊:Current Cancer Drug Targets
[Bentham Science]
日期:2015-11-10
卷期号:15 (9): 792-802
被引量:8
标识
DOI:10.2174/156800961509151110143001
摘要
Dysregulation of epidermal growth factor receptor (EGFR) signaling due to receptor overexpression or activating mutation is associated with cancer cell proliferation, metastasis, and survival. EGFR has become an important therapeutic target for non-small cell lung cancer (NSCLC), and several EGFR-targeted agents, such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs), have been developed. The EGFR-TKIs gefitinib, erlotinib, and afatinib have been approved for the treatment of advanced NSCLC, and sensitivity to these drugs has been shown to be associated with the presence of EGFR mutations. Various mAbs to EGFR have also been evaluated in preclinical and clinical studies. In particular, phase III trials have shown a clinically significant survival benefit for addition of the anti-EGFR mAbs cetuximab or necitumumab to a platinum doublet in chemotherapy-naïve patients with advanced NSCLC. We here summarize the results of completed and ongoing clinical trials of EGFR-targeted mAbs for the treatment of NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI